University of Florida - Mt. Sinai Medical Center AD Research Center

佛罗里达大学西奈山医学中心 AD 研究中心

• 批准号: 9753814
• 负责人: Todd E Golde
• 金额: $ 140.53万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-15 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9753814
• 关键词: Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Autopsy; Biological Markers; Brain; Brain imaging; Censuses; Clinical; Clinical Sciences; Clinical assessments; Cognitive; Communities; Consent; Country; Data; Data Set; Data Sources; Dementia; Diagnosis; Diagnostic; Disease; Early Diagnosis; Education; Education and Outreach; Educational Activities; Elderly; Enrollment; Ensure; Epidemic; Evaluation; Florida; Fostering; Functional Magnetic Resonance Imaging; Funding; Geography; Goals; Health Professional; Hispanics; Image; Immunotherapeutic agent; Impaired cognition; Impairment; Individual; Infrastructure; Institutes; Magnetic Resonance Imaging; Measurement; Measures; Medical; Medical center; Memory Disorders; Mission; Modeling; Neurodegenerative Disorders; Not Hispanic or Latino; Participant; Pathologic; Pathology; Patient Care; Patients; Phase; Pilot Projects; Play; Population; Population Heterogeneity; Positron-Emission Tomography; Preventive therapy; Professional Education; Research; Research Activity; Research Personnel; Research Support; Resources; Risk; Role; Science; Services; Site; Statistical Data Interpretation; Structure; Techniques; Testing; Training; Translational Research; United States; United States National Institutes of Health; Universities; Vision; Water; Work; base; clinical care; cohort; data management; design; effective therapy; ethnic diversity; fighting; functional decline; genetic analysis; human old age (65+); improved; innovation; investigator training; mild cognitive impairment; neuropathology; novel; novel therapeutics; outreach; pre-clinical; prevent; programs; public health relevance; recruit; synergism; tool

DESCRIPTION (provided by applicant): Finding effective treatments and preventative therapies for Alzheimer's disease (AD) is one of the country's most serious unmet medical needs. With ~500,000 AD patients and >3 million at-risk individuals over age 65, Florida is an epicenter of the AD epidemic in the United States; yet, there are no active ADRCs or ADCCs primarily based in the State. In order to further our collective understanding of AD and related dementias, the University of Florida (UF)-Mount Sinai Medical Center (MSMC) AD Research Center (ADRC) will coalesce research efforts within the Wien Memory Disorder Center at MSMC in Miami and the UF in Gainesville. These efforts will capitalize on the clinical population in the Wien Center that is majority Hispanic, the expansive research capabilities at UF, and the infrastructure for translational research provided by the NIH funded UF Clinical and Translational Science Institute. Major goals of the UF-MSMC ADRC are to; i) further elucidate the correlation of early cognitive impairment to various biomarkers of brain structure and function; ii) understand predictors of decline in Hispanic and Non-Hispanic individuals; iii) support translational research efforts that will further the understanding of disease mechanisms; iv) lay the groundwork for improved designs for testing novel therapies for AD and related dementias, and; v) have a broad state-wide educational impact including recruitment of junior investigators into the AD field. In addition to the five required Cores, three Projects are proposed. Project I explores the hypothesis that MRI-based measures of free water can provide important theragnostic information in AD. Project II evaluates new cognitive paradigms that will be more sensitive to the earliest manifestations of AD in Hispanic and non-Hispanic populations. Project III will develop new models of mixed AD pathologies and evaluate immunotherapeutic approaches aimed at modifying these mixed pathologies. Having recognized the need for ADRCs in Florida, there is substantial multi-institutional support for this ADRC and, importantly, supplemental State of Florida legislative funding.

描述（由申请人提供）：寻找有效的治疗和预防阿尔茨海默病（AD）的治疗方法是该国最严重的未满足的医疗需求之一。佛罗里达有约500，000名AD患者和> 300万65岁以上的高危个体，是美国AD流行病的中心;然而，该州没有主要的活性ADRC或ADCC。为了促进我们对AD和相关痴呆症的集体理解，佛罗里达大学（UF）-西奈山医学中心（MSMC）AD研究中心（ADRC）将联合迈阿密MSMC的维恩记忆障碍中心和盖恩斯维尔的UF的研究工作。这些努力将利用维也纳中心的临床人口，主要是西班牙裔，在UF的广泛的研究能力，以及由NIH资助的UF临床和转化科学研究所提供的转化研究的基础设施。UF-MSMC ADRC的主要目标是：i）进一步阐明早期认知障碍与大脑结构和功能的各种生物标志物的相关性; ii）了解西班牙裔和非西班牙裔个体下降的预测因素; iii）支持将进一步理解疾病机制的转化研究工作; iv）为测试AD和相关痴呆症的新疗法的改进设计奠定基础;以及; v）具有广泛的全州教育影响，包括招聘初级调查员进入AD领域。除了所需的五个核心外，还提出了三个项目。项目I探讨了基于MRI的自由水测量可以提供AD重要的治疗诊断信息的假设。项目II评估了新的认知范式，这将是更敏感的最早表现的AD在西班牙裔和非西班牙裔人口。项目III将开发混合AD病理的新模型，并评估旨在改变这些混合病理的免疫学方法。在认识到佛罗里达需要ADRC后，该ADRC得到了大量的多机构支持，重要的是，佛罗里达州的补充立法资金。

项目成果

Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model.

• DOI: 10.1002/glia.23981
• 发表时间: 2021-08
• 期刊: Glia
• 影响因子: 6.2
• 作者: Smit T;Deshayes NAC;Borchelt DR;Kamphuis W;Middeldorp J;Hol EM
• 通讯作者: Hol EM

Sex significantly predicts medial temporal volume when controlling for the influence of ApoE4 biomarker and demographic variables: A cross-ethnic comparison.

• DOI: 10.1017/s1355617723000358
• 发表时间: 2023-06
• 期刊: Journal of the International Neuropsychological Society
• 影响因子: 2.6
• 作者: P. Garcia;L. Mendoza;D. Padron;A. Duarte;R. Duara;D. Loewenstein;M. Greig‐Custo;W. Barker;R. Curiel;M. Rosselli;Miriam J. Rodriguez

Effects of Bilingualism on Verbal and Nonverbal Memory Measures in Mild Cognitive Impairment.

• DOI: 10.1017/s135561771800070x
• 发表时间: 2019-01
• 期刊: Journal of the International Neuropsychological Society : JINS
• 作者: Rosselli M;Loewenstein DA;Curiel RE;Penate A;Torres VL;Lang M;Greig MT;Barker WW;Duara R
• 通讯作者: Duara R

Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.

淀粉样蛋白α-突触核蛋白种子不会始终诱导小鼠的快速，广泛的病理。

• DOI: 10.1007/s00401-014-1268-0
• 发表时间: 2014-05
• 期刊: Acta neuropathologica
• 影响因子: 12.7
• 作者: Sacino AN;Brooks M;Thomas MA;McKinney AB;McGarvey NH;Rutherford NJ;Ceballos-Diaz C;Robertson J;Golde TE;Giasson BI
• 通讯作者: Giasson BI

The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals.

ATN 阿尔茨海默病生物标志物谱对认知正常个体的预后价值。

• DOI: 10.1212/wnl.0000000000007223
• 发表时间: 2019
• 期刊: Neurology
• 影响因子: 9.9
• 作者: Vos,StephanieJB;Duara,Ranjan
• 通讯作者: Duara,Ranjan